It is not only you who are “cut leeks” by the stock market, but also a century old brand Yunnan Baiyao Group Co.Ltd(000538) .
On the evening of March 25, Yunnan Baiyao Group Co.Ltd(000538) disclosed the performance report of 2021, due to the loss of 1.929 billion yuan from the change of fair value, Yunnan Baiyao Group Co.Ltd(000538) net profit decreased by 49.17% year-on-year to 2.804 billion yuan, which became the first decline in net profit attributable to the parent company in recent 20 years
After the loss of 1.5 billion yuan in stock speculation in the third quarter of 2021 triggered a heated discussion in the market, Yunnan Baiyao Group Co.Ltd(000538) voting heart will gradually reduce its positions and will not continue to increase its holdings. However, Yunnan Baiyao Group Co.Ltd(000538) ‘s diversified steps have not stopped. It has set foot in toothpaste, shampoo and industrial marijuana, and has to march into special medical food, medical skin care products and other fields.
Yunnan Baiyao Group Co.Ltd(000538) what kind of pharmaceutical company will it become in the future?
annual net profit fell for the first time
stock speculation loss of nearly 2 billion
On the evening of March 25, Yunnan Baiyao Group Co.Ltd(000538) disclosed the annual report of 2021. The company achieved an operating revenue of 36.374 billion yuan, an increase of 11.09% year-on-year; The net profit was 2.804 billion yuan, a year-on-year decrease of 49.17%, which was the first annual net profit decline of Yunnan Baiyao Group Co.Ltd(000538) in recent 20 years.
The failure of securities investment is the reason affecting the net profit of Yunnan Baiyao Group Co.Ltd(000538) 2021. According to the financial report of 2021, Yunnan Baiyao Group Co.Ltd(000538) the profit and loss from changes in fair value was -1.929 billion yuan, compared with 2.24 billion yuan in the same period of last year
The impact of stock losses on Yunnan Baiyao Group Co.Ltd(000538) performance is also reflected in the third quarterly report of 2021. In October 2021, Yunnan Baiyao Group Co.Ltd(000538) released the third quarterly report. The net profit of the company decreased by 42.38% year-on-year to 2.451 billion yuan, and the profit and loss from changes in fair value during the holding period of trading financial assets was – 1.55 billion yuan.
At that time, in view of the loss of 1.5 billion yuan in stock speculation, Yunnan Baiyao Group Co.Ltd(000538) responded that the company fully listened to the opinions and suggestions of the majority of investors on the development of the company and strictly controlled the investment scale in the secondary market on the basis of the original risk control measures. In 2022, within the limit approved by the board of directors, the company will gradually reduce its positions and will not continue to increase its holdings 2021 financial report shows that Yunnan Baiyao Group Co.Ltd(000538) disposed of some equity instrument investments, and the proportion of trading financial assets decreased by 11.23% to 4.72 billion yuan
slow performance growth
test water, medical beauty and catering
According to Jiang Han, senior researcher of Pangu think tank, from the perspective of overall market development, Yunnan Baiyao Group Co.Ltd(000538) chose stock speculation as its important market development direction. The core reason for itself is that Yunnan Baiyao Group Co.Ltd(000538) its performance growth is relatively slow
As a pharmaceutical enterprise with a market value of 100 billion yuan, Yunnan Baiyao Group Co.Ltd(000538) made its fortune by relying on Yunnan Baiyao Group Co.Ltd(000538) series products, and then expanded to the field of daily chemicals, and created great health products such as toothpaste and yangyuanqing shampoo. At present, the four major businesses of Yunnan Baiyao Group Co.Ltd(000538) are pharmaceutical business department, health products business department, traditional Chinese medicine resources business department and pharmaceutical business.
According to the data, the profitability of Yunnan Baiyao Group Co.Ltd(000538) has been in a downward trend in recent years. From 2018 to 2021, the gross profit margin of the company decreased from 31.25% to 27.15%, and the net profit margin decreased from 12.88% to 7.69%.
Securities investment has high risks, and Yunnan Baiyao Group Co.Ltd(000538) continues to explore new businesses against the background of weak performance growth.
special medical food is a new direction of Yunnan Baiyao Group Co.Ltd(000538) aiming according to the financial report of 2021, Yunnan Baiyao Group Co.Ltd(000538) main R & D expenses increased by 82.99% year-on-year to RMB 331 million, and two major projects including R & D and registration of special medical food and R & D and development of Caiji biomedical skin care products were added Yunnan Baiyao Group Co.Ltd(000538) hope to create new performance growth points.
Prior to this, Yunnan Baiyao Group Co.Ltd(000538) also focused on the medical beauty business since 2022, Yunnan Baiyao Group Co.Ltd(000538) has repeatedly stated on the investor interaction platform that the company plans to open 8 medical clinics in Beijing and Shanghai by December 2022. In the financial report of 2021, Yunnan Baiyao Group Co.Ltd(000538) the revenue composition column also added the hotel catering industry, realizing a revenue of 2.01 million yuan.
In terms of diversified business, the layout of Yunnan Baiyao Group Co.Ltd(000538) the leading enterprise of traditional Chinese Medicine from medicine to toothpaste, shampoo, tea, industrial marijuana, medical beauty and special medical food , whether the new business can bring growth to Yunnan Baiyao Group Co.Ltd(000538) or drag remains to be tested by the marketp align=”center”>